1. Gruber SA, Silveri MM, Yurgelun-Todd DA.
Neuropsychological consequences of opiate use.
Neuropsychol Rev 2007; 17(3): 299-315.
2. Kalechstein AD, Newton TF, Green M.
Methamphetamine dependence is associated with
neurocognitive impairment in the initial phases of
abstinence. J Neuropsychiatry Clin Neurosci 2003;
15(2): 215-20.
3. Meredith CW, Jaffe C, Ang-Lee K, Saxon AJ.
Implications of chronic methamphetamine use: a
literature review. Harv Rev Psychiatry 2005; 13(3):
141-54.
4. Yoshida T. Use and misuse of amphetamines: an
international overview. In: Klee H, editor.
Amphetamine misuse: International perspectives on
current trends. Cardiff, UK: Harwood Academic
Publishers; 1997. p. 1-16.
5. Winslow BT, Voorhees KI, Pehl KA.
Methamphetamine abuse. Am Fam Physician 2007;
76(8): 1169-74.
6. Goodchild JH, Donaldson M. Methamphetamine
abuse and dentistry: a review of the literature and
presentation of a clinical case. Quintessence Int
2007; 38(7): 583-90.
7. Mariotti KC, Rossato LG, Froehlich PE, Limberger
RP. Amphetamine-type medicines: A review of
pharmacokinetics, pharmacodynamics, and
toxicological aspects. Curr Clin Pharmacol 2013;
8(4): 350-7.
8. Klasser GD, Epstein J. Methamphetamine and its
impact on dental care. J Can Dent Assoc 2005;
71(10): 759-62.
9. Radfar SR, Rawson RA. Current research on
methamphetamine: epidemiology, medical and
psychiatric effects, treatment, and harm reduction
efforts. Addict Health 2014; 6(3-4): 146-54.
10. Degenhardt L, Mathers B, Guarinieri M, Panda S,
Phillips B, Strathdee SA, et al. Meth/amphetamine
use and associated HIV: Implications for global
policy and public health. Int J Drug Policy 2010;
21(5): 347-58.
11. Yeo KK, Wijetunga M, Ito H, Efird JT, Tay K, Seto
TB, et al. The association of methamphetamine use
and cardiomyopathy in young patients. Am J Med
2007; 120(2): 165-71.
12. Vearrier D, Greenberg MI, Miller SN, Okaneku JT,
Methamphetamine Consumption in Iranian Youths Darvishzadeh et al.
Addict Health, Summer 2019; Vol 11, No 3 145
http://ahj.kmu.ac.ir, 06 July
Haggerty DA. Methamphetamine: history,
pathophysiology, adverse health effects, current
trends, and hazards associated with the clandestine
manufacture of methamphetamine. Dis Mon 2012;
58(2): 38-89.
13. Wu LT, Schlenger WE, Galvin DM. Concurrent use
of methamphetamine, MDMA, LSD, ketamine,
GHB, and flunitrazepam among American youths.
Drug Alcohol Depend 2006; 84(1): 102-13.
14. Darke S, Kaye S, McKetin R, Duflou J. Major
physical and psychological harms of
methamphetamine use. Drug Alcohol Rev 2008;
27(3): 253-62.
15. Petit A, Karila L, Chalmin F, Lejoyeux M.
Methamphetamine addiction: A review of the
literature. J Addict Res Ther 2012; S1:006.
16. Mooney LJ, Glasner-Edwards S, Marinelli-Casey P,
Hillhouse M, Ang A, Hunter J, et al. Health conditions
in methamphetamine-dependent adults 3 years after
treatment. J Addict Med 2009; 3(3): 155-63.
17. Callaghan RC, Cunningham JK, Allebeck P,
Arenovich T, Sajeev G, Remington G, et al.
Methamphetamine use and schizophrenia: A
population-based cohort study in California. Am J
Psychiatry 2012; 169(4): 389-96.
18. Callaghan RC, Cunningham JK, Sajeev G, Kish SJ.
Incidence of Parkinson's disease among hospital
patients with methamphetamine-use disorders. Mov
Disord 2010; 25(14): 2333-9.
19. Callaghan RC, Cunningham JK, Sykes J, Kish SJ.
Increased risk of Parkinson's disease in individuals
hospitalized with conditions related to the use of
methamphetamine or other amphetamine-type drugs.
Drug Alcohol Depend 2012; 120(1-3): 35-40.
20. Sommers I, Baskin D. Methamphetamine use and
violence. J Drug Issues 2006; 36(1): 77-96.
21. Nikfarjam A, Shokoohi M, Shahesmaeili A,
Haghdoost AA, Baneshi MR, Haji-Maghsoudi S, et
al. National population size estimation of illicit drug
users through the network scale-up method in 2013
in Iran. Int J Drug Policy 2016; 31: 147-52.
22. Bagheri N, Mirzaee M, Jahani Y, Karamouzian M,
Sharifi H. Correlates of methamphetamine use
among young Iranians: Findings of a populationbased survey in 2013. Am J Addict 2017; 26(7):
731-7.
23. Saw YM, Saw TN, Yasuoka J, Chan N, Kham NPE,
Khine W, et al. Gender difference in early initiation
of methamphetamine use among current
methamphetamine users in Muse, Northern Shan
State, Myanmar. Harm Reduct J 2017; 14(1): 21.
24. Noori R, Farhoudian A, Naranjiha H, Farhadi M H,
Dolan K, et al. Comparison of characteristics of
methamphetamine versus opiate users in Tehran,
Iran. Int J High Risk Behav Addict 2016; 5(4):
e28815.
25. Dickerson DL, Fisher DG, Reynolds GL, Baig S,
Napper LE, Anglin MD. Substance use patterns
among high-risk American Indians/Alaska Natives
in Los Angeles County. Am J Addict 2012; 21(5):
445-52.
26. Hides L, Dawe S, McKetin R, Kavanagh DJ, Young
RM, Teesson M, et al. Primary and substanceinduced psychotic disorders in methamphetamine
users. Psychiatry Res 2015; 226(1): 91-6.
27. Svingen L, Dykstra RE, Simpson JL, Jaffe AE,
Bevins RA, Carlo G, et al. Associations between
family history of substance use, childhood trauma,
and age of first drug use in persons with
methamphetamine dependence. J Addict Med 2016;
10(4): 269-73.
28. Sattah MV, Supawitkul S, Dondero TJ, Kilmarx PH,
Young NL, Mastro TD, et al. Prevalence of and risk
factors for methamphetamine use in northern Thai
youth: results of an audio-computer-assisted selfinterviewing survey with urine testing. Addiction
2002; 97(7): 801-8.
29. Herman-Stahl MA, Krebs CP, Kroutil LA, Heller
DC. Risk and protective factors for nonmedical use
of prescription stimulants and methamphetamine
among adolescents. J Adolesc Health 2006; 39(3):
374-80.
30. Shokoohi M, Karamouzian M, Mirzazadeh A,
Haghdoost A, Rafierad AA, Sedaghat A, et al. HIV
knowledge, attitudes, and practices of young people
in Iran: Findings of a national population-based
survey in 2013. PLoS One 2016; 11(9): e0161849.
31. Lin SK, Ball D, Hsiao CC, Chiang YL, Ree SC,
Chen CK. Psychiatric comorbidity and gender
differences of persons incarcerated for
methamphetamine abuse in Taiwan. Psychiatry Clin
Neurosci 2004; 58(2): 206-12.
32. Rungnirundorn T, Verachai V, Gelernter J, Malison
RT, Kalayasiri R. Sex Differences in
methamphetamine use and dependence in a Thai
treatment center. J Addict Med 2017; 11(1): 19-27.
33. Dluzen DE, Liu B. Gender differences in
methamphetamine use and responses: A review.
Gend Med 2008; 5(1): 24-35.
34. Farnia V, Alikhani M, Jalali A, Golshani S, Salemi
S, Hookari S, et al. The role of attachment styles and
perceived social support in prediction of
methamphetamine abuse. J Subst Abuse 2018; 23(4):
377-83.
35. Dong H, Yang M, Liu L, Zhang C, Liu M, Shen Y,
et al. Comparison of demographic characteristics and
psychiatric comorbidity among methamphetamine-,
heroin- and methamphetamine-heroin co- dependent
males in Hunan, China. BMC Psychiatry 2017;
17(1): 183.
Methamphetamine Consumption in Iranian Youths Darvishzadeh et al.
146 Addict Health, Summer 2019; Vol 11, No 3
http://ahj.kmu.ac.ir, 06 July
36. Barati M, Ahmadpanah M, Soltanian AR.
Prevalence and factors associated with
methamphetamine use among adult substance
abusers. J Res Health Sci 2014; 14(3): 221-6.
37. Sherman SG, Gann D, German D, Sirirojn B,
Thompson N, Aramrattana A, et al. A qualitative
study of sexual behaviours among methamphetamine
users in Chiang Mai, Thailand: a typology of risk.
Drug Alcohol Rev 2008; 27(3): 263-9.
38. Molitor F, Truax SR, Ruiz JD, Sun RK. Association
of methamphetamine use during sex with risky
sexual behaviors and HIV infection among
non-injection drug users. West J Med 1998; 168(2):
93-7.
39. Semple SJ, Patterson TL, Grant I. The context of
sexual risk behavior among heterosexual
methamphetamine users. Addict Behav 2004; 29(4):
807-10.
40. Yen CF. Relationship between methamphetamine
use and risky sexual behavior in adolescents.
Kaohsiung J Med Sci 2004; 20(4): 160-5.
41. Boostani D, Karamizadeh E. Conditions and
strategies of crystal (Methamphetamine)
consumption among addicted women (Case study:
Kerman city). Woman in Development and Politics
(Women's Research) 2017; 15(1): 1-20. [In Persian].
)